Justin Zelin
Stock Analyst at BTIG
(1.40)
# 3,362
Out of 4,876 analysts
37
Total ratings
23.53%
Success rate
-2.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.79 | +115.05% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $21.52 | +95.17% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.41 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $22.29 | +178.15% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $5.69 | +1,481.72% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.48 | +710.81% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $13.38 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $28.17 | +343.73% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $4.16 | +549.04% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.03 | +77,569.90% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $32.02 | +184.20% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.67 | +1,391.20% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.72 | +2,113.31% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $9.95 | +271.86% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $9.29 | +276.75% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $33.48 | +168.82% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $5.73 | +441.01% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $67.70 | -77.10% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.63 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.30 | +669.23% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.79
Upside: +115.05%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $21.52
Upside: +95.17%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.41
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $22.29
Upside: +178.15%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $5.69
Upside: +1,481.72%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.48
Upside: +710.81%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.38
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $28.17
Upside: +343.73%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $4.16
Upside: +549.04%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.03
Upside: +77,569.90%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $32.02
Upside: +184.20%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.67
Upside: +1,391.20%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.72
Upside: +2,113.31%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $9.95
Upside: +271.86%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $9.29
Upside: +276.75%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $33.48
Upside: +168.82%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $5.73
Upside: +441.01%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $67.70
Upside: -77.10%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.63
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.30
Upside: +669.23%